Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285787 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
A Phase 2 study of End Stage Renal Disease (ESRD), sponsored by Epizon Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05285787 is a Phase 2 study of End Stage Renal Disease (ESRD) that has completed, run by Epizon Pharma. The registered enrollment target is 18 participants, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05285787, a Phase 2 study of End Stage Renal Disease (ESRD), has completed, sponsored by Epizon Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with End Stage Renal Disease (ESRD) are prone to early and accelerated vascular calcification. Both the prevalence and extent of the vascular calcification are predictive for cardiovascular morbidity and all-cause mortality in this population. There is a growing body of evidence suggesting that dialysis patients have a primary, functional deficiency of Vitamin K2 as evidenced by reduced levels of circulating biomarkers including carboxylated forms of Matrix Gla Protein (MGP), Osteocalcin, and Fetuin-A, which are important inhibitors of vascular calcification. Decreased levels of Vitamin K2 are known to lead to microvascular calcification and are associated with dermatological and cardiovascular conditions such as calciphylaxis and peripheral arterial disease (PAD). The purpose of this Phase 2 study is to examine the safety and pharmacokinetics of EPN-701 (menaquinone-7; MK-7) and to assess the effects on certain circulating biomarkers when MK-7 is orally administered once daily for 14 days.
Conditions Studied
Interventions
- DRUG EPN-701 (Oral)
Study Locations (1)
Georgia
- Southeastern Clinical Research Institute, LLC - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05285787
The ClinicalTrials.gov registry entry for NCT05285787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower). The listed sponsor is Epizon Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 1 intervention - of which EPN-701 (Oral) is the first listed.
NCT05285787 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05285787 about?
NCT05285787 is a clinical study titled "A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)". Patients with End Stage Renal Disease (ESRD) are prone to early and accelerated vascular calcification. Both the prevalence and extent of the vascular calcification are predictive for cardiovascular morbidity and all-cause mortality in this population. There is a growing body of evidence suggesting ...
What is the current status of trial NCT05285787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-03-01. Estimated completion is 2021-04-30.
What conditions does trial NCT05285787 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD).
What interventions are being tested in trial NCT05285787?
The interventions under investigation include: EPN-701 (Oral) (DRUG).
Who is sponsoring clinical trial NCT05285787?
This trial is sponsored by Epizon Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05285787 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.